MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

AcelRx Pharmaceuticals Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+532.91% upside

AcelRx Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sty 2026, 23:07 UTC

Earnings

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 sty 2026, 21:27 UTC

Earnings

Texas Instruments 4Q Sales Rise, Profit Falls

27 sty 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 sty 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 sty 2026, 23:19 UTC

Earnings

SK Innovation Posts Net Loss for Second Consecutive Year

27 sty 2026, 23:19 UTC

Earnings

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 sty 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27 sty 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 sty 2026, 23:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 sty 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 sty 2026, 22:06 UTC

Earnings

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 sty 2026, 21:51 UTC

Earnings

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 sty 2026, 21:43 UTC

Earnings

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 sty 2026, 21:41 UTC

Earnings

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 sty 2026, 21:38 UTC

Earnings

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 sty 2026, 21:32 UTC

Earnings

Ampol: Modest Profit From F&I International in 2025

27 sty 2026, 21:32 UTC

Earnings

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 sty 2026, 21:31 UTC

Earnings

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 sty 2026, 21:31 UTC

Earnings

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 sty 2026, 21:30 UTC

Earnings

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 sty 2026, 21:28 UTC

Earnings

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Peer Comparison

Price change

AcelRx Pharmaceuticals Inc Forecast

Price Target

By TipRanks

532.91% upside

12 Months Forecast

Average 5 USD  532.91%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forAcelRx Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financials

$

help-icon Live chat